117
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Encapsulated n-Butylidenephthalide Efficiently Crosses the Blood–Brain Barrier and Suppresses Growth of Glioblastoma

, , , &
Pages 749-760 | Published online: 31 Jan 2020

References

  • Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-127157931
  • Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013;126(6):931–937. doi:10.1007/s00401-013-1163-023955565
  • Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6(3):217–223. [ discussion 223-214]. doi:10.1111/j.1750-3639.1996.tb00848.x8864278
  • Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra070812618669428
  • Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683–2710. doi:10.1101/gad.159670717974913
  • Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
  • Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395–403. doi:10.1016/S1470-2045(14)70011-725079102
  • Lee YM, Lee YR, Kim CS, et al. Cnidium officinale extract and butylidenephthalide inhibits retinal neovascularization in vitro and in vivo. BMC Complement Altern Med. 2016;16:231. doi:10.1186/s12906-016-1216-827435599
  • Yen SY, Chen SR, Hsieh J, et al. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion. Oncogene. 2016;35(17):2156–2165. doi:10.1038/onc.2015.27726257061
  • Chen YL, Jian MH, Lin CC, et al. The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy. Mol Pharmacol. 2008;74(4):1046–1058. doi:10.1124/mol.107.04480018577687
  • Liu PY, Sheu JJ, Lin PC, et al. Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma. Invest New Drugs. 2012;30(1):79–89. doi:10.1007/s10637-010-9518-z20809206
  • Lin PC, Chen YL, Chiu SC, et al. Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. J Neurochem. 2008;106(3):1017–1026. doi:10.1111/j.1471-4159.2008.05432.x18419761
  • Chang LF, Lin PC, Ho LI, et al. Overexpression of the orphan receptor Nur77 and its translocation induced by PCH4 may inhibit malignant glioma cell growth and induce cell apoptosis. J Surg Oncol. 2011;103(5):442–450. doi:10.1002/jso.2180921246566
  • Huang MH, Lin SZ, Lin PC, et al. Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability. Tumour Biol. 2014;35(5):4875–4884. doi:10.1007/s13277-014-1639-024464249
  • Lin PC, Lin SZ, Chen YL, et al. Butylidenephthalide suppresses human telomerase reverse transcriptase (TERT) in human glioblastomas. Ann Surg Oncol. 2011;18(12):3514–3527. doi:10.1245/s10434-011-1644-021553143
  • Tsai NM, Chen YL, Lee CC, et al. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem. 2006;99(4):1251–1262. doi:10.1111/j.1471-4159.2006.04151.x16987298
  • Deng S, Chen SN, Yao P, et al. Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod. 2006;69(4):536–541. doi:10.1021/np050301s16643021
  • Yan R, Ko NL, Li SL, Tam YK, Lin G. Pharmacokinetics and metabolism of ligustilide, a major bioactive component in Rhizoma Chuanxiong, in the rat. Drug Metab Dispos. 2008;36(2):400–408. doi:10.1124/dmd.107.01770718039808
  • Harn HJ, Lin SZ, Lin PC, et al. Local interstitial delivery of z-butylidenephthalide by polymer wafers against malignant human gliomas. Neuro-Oncology. 2011;13(6):635–648. doi:10.1093/neuonc/nor02121565841
  • Lin YL, Chang KF, Huang XF, et al. Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme. Int J Nanomedicine. 2015;10:6009–6020. doi:10.2147/IJN.S8579026451107
  • Liu YK, Lin YL, Chen CH, et al. A unique and potent protein binding nature of liposome containing polyethylenimine and polyethylene glycol: a nondisplaceable property. Biotechnol Bioeng. 2011;108(6):1318–1327. doi:10.1002/bit.2304821192002
  • Lin YL, Liu YK, Tsai NM, et al. A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells. Nanomed. 2012;8(3):318–327. doi:10.1016/j.nano.2011.06.011
  • Lin YL, Chen CH, Wu HY, et al. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex. J Nanobiotechnology. 2016;14:11. doi:10.1186/s12951-016-0163-326892504
  • Chen CH, Lin YL, Liu YK, et al. Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch. Int J Nanomedicine. 2012;7:607–621. doi:10.2147/IJN.S2809722346354
  • Lin YL, Tsai NM, Chen CH, et al. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies. J Nanobiotechnology. 2019;17(1):25. doi:10.1186/s12951-019-0457-330728015
  • Lin YL, Chen CH, Liu YK, et al. Lipo-PEG-PEI complex as an intracellular transporter for protein therapeutics. Int J Nanomedicine. 2019;14:1119–1130. doi:10.2147/IJN.S18897030863049
  • Wang N, Sun P, Lv M, Tong G, Jin X, Zhu X. Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy. Biomater Sci. 2017;5:1041–1050. doi:10.1039/C7BM00133A28378865
  • Neves AR, Queiroz JF, Lima SAC, Reis S. Apo E-functionalization of solid lipid nanoparticles enhances brain drug delivery: uptake mechanism and transport pathways. Bioconjug Chem. 2017;28(4):995–1004. doi:10.1021/acs.bioconjchem.6b0070528355061
  • Tsai NM, Lin SZ, Lee CC, et al. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res. 2005;11(9):3475–3484. doi:10.1158/1078-0432.CCR-04-182715867250
  • Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892–6899. doi:10.1158/0008-5472.CAN-04-133715466178
  • Venkatesan S, Lamfers ML, Dirven CM, Leenstra S. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma. CNS Oncol. 2016;5(2):77–90. doi:10.2217/cns-2015-000526986934
  • Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 1998;16(3):311–320. doi:10.1038/sj.onc.12015439467956
  • Yang Y, Chin A, Zhang L, Lu J, Wong RW. The role of traditional Chinese medicines in osteogenesis and angiogenesis. Phytother Res. 2014;28(1):1–8. doi:10.1002/ptr.495923494901
  • Lin PL, Li ZC, Xie RF, Wang YH, Zhou X. Compatibility study of Danggui Buxue Tang on chemical ingredients, angiogenesis and endothelial function. Sci Rep. 2017;7:45111. doi:10.1038/srep4511128327640
  • Yeh JC, Cindrova-Davies T, Belleri M, et al. The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis. 2011;14(2):187–197. doi:10.1007/s10456-011-9202-821327473